The relationship between acromegaly and hepatic steatosis: insights from FibroScan imaging
Journal of Endocrinological Investigation · 2026
DOI: 10.1007/s40618-025-02799-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Endocrinological Investigation, 2026. Verfasst von Tugce Apaydin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Marmara University School of Medicine, Istanbul, Turkey. tugce.apaydin@marmara.edu.tr. Hauptthemen laut MEDLINE: Acromegaly, Fatty Liver, Elasticity Imaging Techniques. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marmara University.
Abstract (Originalsprache)
Purpose
The relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and acromegaly is unclear due to the complex metabolic effects of growth hormone (GH). GH stimulates gluconeogenesis, glycogenolysis, and lipolysis, increasing free fatty acids, a risk factor for MASLD, but may also protect against hepatic fat accumulation. In this study, we aimed to evaluate the impact of acromegaly and GH levels on liver steatosis and fibrosis using non-invasive FibroScan imaging.
Methods
This cross-sectional study included 58 patients with acromegaly, 61 age- and sex-matched metabolically comparable controls, and 82 healthy controls. Hepatic steatosis and fibrosis were assessed via controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) by vibration-controlled transient elastography. Moderate to severe steatosis was defined as CAP > 260 dB/m, and significant fibrosis as LSM ≥ 8.0 kPa.
Results
Both acromegaly patients and metabolically healthy individuals exhibited lower CAP (241.8 ± 50.0 and 231.7 ± 51.9 dB/m) and LSM (4.7 ± 1.4 and 4.8 ± 1.8 kPa) scores than metabolically matched controls (CAP 281.7 ± 61.2 dB/m; LSM 5.5 ± 1.8 kPa; CAP p < 0.001; LSM p = 0.012). Moderate-to-severe steatosis was observed in 36.2% of acromegaly patients, 27.7% of healthy individuals, and 68.8% of metabolically matched controls ( p < 0.001), while significant liver fibrosis occurred in 5.2%, 7.3%, and 14.7%, respectively ( p = 0.154). GH levels were lower in acromegaly patients with MASLD ( p < 0.001) compared to those without. CAP correlated negatively with GH and positively with BMI, waist circumference, and triglycerides, whereas LSM correlated positively with age, BMI, and triglycerides.
Conclusions
Hepatic steatosis was less frequent in acromegaly than in metabolically comparable individuals, and GH was inversely associated with hepatic steatosis scores, possibly suggesting a protective role of GH independent of metabolic comorbidities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Marmara University School of Medicine, Istanbul, Turkey. tugce.apaydin@marmara.edu.tr.
- Department of Gastroenterology, Marmara University School of Medicine, Istanbul, Turkiye, Turkey.
- Department of Gastroenterology, Recep Tayyip Erdogan University School of Medicine, Rize, Turkey.
- Department of Endocrinology and Metabolism, Marmara University School of Medicine, Istanbul, Turkey.
Förderung
- Marmara University
Zitieren
APA
Apaydin, T., Kani, H. T., Keklikkiran, C., Yilmaz, Y., & Yavuz, D. G. (2026). The relationship between acromegaly and hepatic steatosis: insights from FibroScan imaging. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-025-02799-8
Vancouver
Apaydin T, Kani HT, Keklikkiran C, Yilmaz Y, Yavuz DG. The relationship between acromegaly and hepatic steatosis: insights from FibroScan imaging. Journal of Endocrinological Investigation. 2026. doi:10.1007/s40618-025-02799-8
BibTeX
@article{Apaydin2026,
author = {Apaydin, Tugce and Kani, Haluk Tarik and Keklikkiran, Caglayan and Yilmaz, Yusuf and Yavuz, Dilek Gogas},
title = {The relationship between acromegaly and hepatic steatosis: insights from FibroScan imaging},
journal = {Journal of Endocrinological Investigation},
year = {2026},
doi = {10.1007/s40618-025-02799-8}
}
EUVIMED